Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
EYEN Stock Summary
Top 10 Correlated ETFs
EYEN
In the News
Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript
Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
US FDA approves Eyenovia's eye drug, Formosa Pharma says
The U.S. Food and Drug Administration approved Eyenovia's eye drops to reduce inflammation and pain in patients who have undergone eye surgery, Formosa Pharmaceuticals said on Monday.
Eyenovia: Racing Toward The Finish Line
Eyenovia has received FDA approval for its Optejet system, which revolutionizes how eye medications are dosed, resolving limitations and adverse events caused by traditional eye droppers. The company's manufacturing facilities, including two in the USA and one in Mexico, have received FDA certification, ensuring the safety and quality of their products. Eyenovia is preparing for the official launch of its first FDA-approved product, MydCombi, and has upcoming events, including financial results and an FDA decision for another drug.
7 Promising Penny Stocks With the Potential to Defy Expectations
You know you want it. High-potential penny stocks that is.
Eyenovia, Inc. (EYEN) Q3 2023 Earnings Call Transcript
Eyenovia, Inc. (NASDAQ:EYEN ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Glenn Garmont - LifeSci Partners, IR Michael Rowe - Chief Executive Officer John Gandolfo - Chief Financial Officer Bren Kern - Chief Operating Officer Conference Call Participants John Boyle - William Blair Raymond Wu - Ladenburg Thalmann Len Yaffe - Stoc*Doc Partners Operator Good day, ladies and gentlemen. And welcome to Eyenovia's Third Quarter of 2023 Earnings Conference Call.
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.
Eyenovia to Report Third Quarter 2023 Results on Monday, November 13
Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
7 Penny Stocks To Buy Now According To Analysts, Targets Up To 751%
The penny stock market is an enticing yet volatile landscape for investors seeking big rewards. While the chance to uncover the next hidden gem before it rockets higher is enticing.
EYEN Financial details
EYEN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.09 | 0.53 | 0 | 0 | |
Net income per share | -1.46 | -0.94 | -0.49 | -0.82 | -0.66 | |
Operating cash flow per share | -1.32 | -0.3 | -0.79 | -0.75 | -0.58 | |
Free cash flow per share | -1.33 | -0.32 | -0.85 | -0.77 | -0.68 | |
Cash per share | 0.99 | 1.35 | 0.74 | 0.68 | 0.36 | |
Book value per share | 0.82 | 0.73 | 0.78 | 0.51 | 0.22 | |
Tangible book value per share | 0.82 | 0.73 | 0.78 | 0.51 | 0.17 | |
Share holders equity per share | 0.82 | 0.73 | 0.78 | 0.51 | 0.22 | |
Interest debt per share | 0 | 0.02 | 0.29 | 0.34 | 0.42 | |
Market cap | 64.29M | 127.59M | 105.3M | 54.85M | 85.35M | |
Enterprise value | 50.18M | 99.68M | 92.98M | 42.11M | 86.61M | |
P/E ratio | -3.06 | -6.48 | -8.1 | -1.98 | -3.13 | |
Price to sales ratio | 0 | 63.8 | 7.52 | 0 | 22.54K | |
POCF ratio | -3.4 | -19.99 | -5.04 | -2.18 | -3.58 | |
PFCF ratio | -3.37 | -19.2 | -4.68 | -2.11 | -3.07 | |
P/B Ratio | 5.48 | 8.34 | 5.14 | 3.18 | 9.48 | |
PTB ratio | 5.48 | 8.34 | 5.14 | 3.18 | 9.48 | |
EV to sales | 0 | 49.84 | 6.64 | 0 | 22.87K | |
Enterprise value over EBITDA | -2.35 | -5.05 | -7.23 | -1.58 | -3.52 | |
EV to operating cash flow | -2.65 | -15.61 | -4.45 | -1.68 | -3.63 | |
EV to free cash flow | -2.63 | -15 | -4.13 | -1.62 | -3.11 | |
Earnings yield | -0.33 | -0.15 | -0.12 | -0.51 | -0.32 | |
Free cash flow yield | -0.3 | -0.05 | -0.21 | -0.47 | -0.33 | |
Debt to equity | 0 | 0.03 | 0.35 | 0.59 | 1.65 | |
Debt to assets | 0 | 0.01 | 0.23 | 0.33 | 0.51 | |
Net debt to EBITDA | 0.66 | 1.41 | 0.96 | 0.48 | -0.05 | |
Current ratio | 4.93 | 1.83 | 1.97 | 6.13 | 1.73 | |
Interest coverage | 0 | -1.16K | -33.28 | -19.5 | -10.71 | |
Income quality | 0.89 | 0.32 | 1.63 | 0.9 | 0.87 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 3.86 | 0.77 | 0 | 2.99K | |
Research and developement to revenue | 0 | 6.63 | 1.04 | 0 | 3.22K | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0.07 | |
Capex to operating cash flow | 0.01 | 0.04 | 0.08 | 0.03 | 0.17 | |
Capex to revenue | 0 | -0.13 | -0.12 | 0 | -1.05K | |
Capex to depreciation | -10.86 | -2.74 | -7.3 | -2.85 | -5.07 | |
Stock based compensation to revenue | 0 | 1.24 | 0.21 | 0 | 659.6 | |
Graham number | 5.19 | 3.91 | 2.94 | 3.08 | 1.81 | |
ROIC | -1.79 | -1.25 | -0.48 | -0.93 | -1.01 | |
Return on tangible assets | -1.43 | -0.58 | -0.41 | -0.89 | -1.02 | |
Graham Net | 0.78 | 0.61 | 0.37 | 0.35 | -0.11 | |
Working capital | 11.44M | 15.19M | 10.83M | 23.13M | 6.92M | |
Tangible asset value | 11.74M | 15.3M | 20.47M | 17.23M | 6.88M | |
Net current asset value | 11.39M | 14.79M | 10.81M | 13.84M | -3.33M | |
Invested capital | 0 | 0.03 | 0.35 | 0.59 | 1.65 | |
Average receivables | 47.62K | 1.53M | 2.39M | 1.49M | 904.15K | |
Average payables | 1.53M | 1.5M | 1.54M | 1.52M | 1.59M | |
Average inventory | -47.62K | 752.38K | 800K | 1.78M | 1.84M | |
Days sales outstanding | 0 | 541.3 | 47.06 | 0 | 60.19K | |
Days payables outstanding | 36.67K | 666.88 | 368.22 | 1.7K | 813.1 | |
Days of inventory on hand | -2.27K | 730 | 0 | 4.24K | 50.92 | |
Receivables turnover | 0 | 0.67 | 7.76 | 0 | 0.01 | |
Payables turnover | 0.01 | 0.55 | 0.99 | 0.22 | 0.45 | |
Inventory turnover | -0.16 | 0.5 | 0 | 0.09 | 7.17 | |
ROE | -1.79 | -1.29 | -0.63 | -1.61 | -3.03 | |
Capex per share | -0.01 | -0.01 | -0.06 | -0.03 | -0.1 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.18 | -0.17 | -0.16 | -0.18 | -0.18 | |
Operating cash flow per share | -0.16 | -0.19 | -0.12 | -0.15 | -0.14 | |
Free cash flow per share | -0.17 | -0.21 | -0.16 | -0.19 | -0.14 | |
Cash per share | 0.68 | 0.49 | 0.46 | 0.52 | 0.33 | |
Book value per share | 0.51 | 0.42 | 0.28 | 0.39 | 0.2 | |
Tangible book value per share | 0.51 | 0.42 | 0.28 | 0.34 | 0.15 | |
Share holders equity per share | 0.51 | 0.42 | 0.28 | 0.39 | 0.2 | |
Interest debt per share | 0.33 | 0.31 | 0.44 | 0.38 | 0.34 | |
Market cap | 54.85M | 132.06M | 90.28M | 66.63M | 94.44M | |
Enterprise value | 42.11M | 124.59M | 88.95M | 61.92M | 95.69M | |
P/E ratio | -2.31 | -5.1 | -3.63 | -2.27 | -2.96 | |
Price to sales ratio | 0 | 0 | 0 | 55.62K | 36.48K | |
POCF ratio | -10.15 | -18.98 | -19.15 | -11.41 | -14.94 | |
PFCF ratio | -9.59 | -16.76 | -15.26 | -8.83 | -14.6 | |
P/B Ratio | 3.18 | 8.35 | 8.58 | 4.22 | 10.49 | |
PTB ratio | 3.18 | 8.35 | 8.58 | 4.22 | 10.49 | |
EV to sales | 0 | 0 | 0 | 51.68K | 36.96K | |
Enterprise value over EBITDA | -8.07 | -23.57 | -15.72 | -9.5 | -13.31 | |
EV to operating cash flow | -7.79 | -17.9 | -18.87 | -10.6 | -15.14 | |
EV to free cash flow | -7.37 | -15.81 | -15.04 | -8.21 | -14.8 | |
Earnings yield | -0.11 | -0.05 | -0.07 | -0.11 | -0.08 | |
Free cash flow yield | -0.1 | -0.06 | -0.07 | -0.11 | -0.07 | |
Debt to equity | 0.59 | 0.7 | 1.53 | 1.01 | 1.65 | |
Debt to assets | 0.33 | 0.38 | 0.55 | 0.46 | 0.51 | |
Net debt to EBITDA | 2.44 | 1.41 | 0.24 | 0.72 | -0.18 | |
Current ratio | 6.13 | 5.09 | 5.73 | 4.05 | 1.73 | |
Interest coverage | -5.94 | -12.02 | -10.68 | 9.6 | -10.97 | |
Income quality | 0.88 | 1.21 | 0.76 | 0.8 | 0.79 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 2.46K | 1.12K | |
Research and developement to revenue | 0 | 0 | 0 | 2.99K | 1.46K | |
Intangibles to total assets | 0 | 0 | 0 | 0.06 | 0.07 | |
Capex to operating cash flow | 0.06 | 0.13 | 0.25 | 0.29 | 0.02 | |
Capex to revenue | 0 | 0 | 0 | -1.42K | -56.1 | |
Capex to depreciation | -3.97 | -4.67 | 123.1 | -5.35 | -0.52 | |
Stock based compensation to revenue | 0 | 0 | 0 | 511.66 | 221.02 | |
Graham number | 1.43 | 1.28 | 1.01 | 1.27 | 0.88 | |
ROIC | -0.18 | -0.22 | -0.23 | -0.19 | -0.3 | |
Return on tangible assets | -0.19 | -0.22 | -0.21 | -0.22 | -0.3 | |
Graham Net | 0.35 | 0.2 | 0.02 | 0.06 | -0.1 | |
Working capital | 23.13M | 20.02M | 19.21M | 19.98M | 6.92M | |
Tangible asset value | 17.23M | 15.81M | 10.52M | 13.66M | 6.88M | |
Net current asset value | 13.84M | 11.43M | 4.45M | 7.45M | -3.33M | |
Invested capital | 0.59 | 0.7 | 1.53 | 1.01 | 1.65 | |
Average receivables | 996.61K | 1.08M | 701.34K | 663.35K | 761.11K | |
Average payables | 1.27M | 1.42M | 1.36M | 1.37M | 1.59M | |
Average inventory | 7.37M | 3.52M | 3.53M | 1.81M | 80.05K | |
Days sales outstanding | 0 | 0 | 0 | 67.44K | 21.71K | |
Days payables outstanding | 1.64K | 640.46 | 435.63 | 107.13K | 563.29 | |
Days of inventory on hand | 4.09K | 1.59K | 1.19K | 3.78K | 35.28 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.05 | 0.14 | 0.21 | 0 | 0.16 | |
Inventory turnover | 0.02 | 0.06 | 0.08 | 0.02 | 2.55 | |
ROE | -0.34 | -0.41 | -0.59 | -0.47 | -0.89 | |
Capex per share | -0.01 | -0.02 | -0.03 | -0.04 | 0 |
EYEN Frequently Asked Questions
What is Eyenovia, Inc. stock symbol ?
Eyenovia, Inc. is a US stock , located in New york of Ny and trading under the symbol EYEN
What is Eyenovia, Inc. stock quote today ?
Eyenovia, Inc. stock price is $0.986 today.
Is Eyenovia, Inc. stock public?
Yes, Eyenovia, Inc. is a publicly traded company.